About ReShape Lifesciences, Inc. - Common Stock (RSLS)
Reshape Lifesciences Inc is a biotechnology company focused on developing innovative medical technologies and solutions for weight management and obesity-related health issues. The company's primary aim is to enhance patient outcomes through its proprietary products, which include minimally invasive procedures designed to aid in weight loss and promote healthier lifestyles. By leveraging advanced engineering and clinical expertise, Reshape Lifesciences seeks to address the growing global health crisis associated with obesity and its complications, ultimately striving to empower individuals to take control of their health through effective interventions. Read More
Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol “HIND.”
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company’s previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol “HIND.”
Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ: RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND.
ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND."
Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved
IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq's stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed.
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Peraso Inc. (NASDAQ: PRSO) has endorsed the NTIA’s revised $42.45B BEAD program, now favoring technology-neutral broadband deployment. The change clears the way for Peraso’s mmWave FWA to deliver 2.5Gbps speeds—offering a cost-effective, fiber-like alternative for rural and underserved areas.
Under the distribution agreement, Recon Supply will distribute ReShape’s portfolio across the Veterans Administration and Department of Defense healthcare systems.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
